Abstract library

2096 results for "tumor progression".
#2739 Epigenetic Landscape of Pancreatic Neuro-Endocrine Tumors Reveals Distinct Cells of Origin and Means of Tumor Progression
Introduction: Pancreatic Neuroendocrine Tumors (PanNETs) arise from cells of the Islets of Langerhans. The majority of PanNETs are non-functional and their cell of origin cannot be defined analysing specific hormone production. Cell of origin assessment has proven importance to identify risk factors, prevent tumour development, and tailor treatment in many malignancies. Recent data on super-enhancer signatures has suggested a potential origin of PanNET from α- or β-cells. We and others have shown that distinct epigenetic profiles assessed by DNA methylation (DNAme) characterize genomic and prognostic groups of PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Annunziata Di Domenico
#862 The Role of Chromogranin A as a Predictor of Radiological Disease Progression in Midgut and Pancreatic Neuroendocrine Tumors
Introduction: Chromogranin A (CgA) is an established neuroendocrine biomarker. However, its role as a predictor of radiological disease progression in all neuroendocrine tumors (NETs) has not been recognised yet.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: MD Roberta E Rossi
#2750 Progression-Free Survival and Clinical Outcomes with Long-Term Use of Telotristat Ethyl in US Clinical Practice
Introduction: Treatment of advanced neuroendocrine tumors aims to relieve symptoms and suppress tumor growth. Primary findings from the TELEACE study suggested telotristat ethyl (TE) may reduce tumor size and impact tumor growth.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: David C. Metz
Authors: Metz D C, Liu E, Joish V N, Huynh L, ...
#724 Contrast-Enhanced Ultrasonography (CEUS) Reliably Predicts Tumor Progression in Pancreatic Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) exhibit a typical vascular pattern in the arterial phase on CEUS. The role of CEUS in the prognostic evaluation of pancreatic NET (pNET) has been poorly investigated.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Michela Del Prete
#2723 Achieving Objective Response in Treatment of Non-Resectable Neuroendocrine Tumors Does Not Predict Longer Time to Progression Compared to Achieving Stable Disease
Introduction: There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally the goal of these treatments are to reduce the tumor load; objective response (OR). Less emphasis has been put on inducing the tumors to stop growing without reduction in total tumor load; stable disease (SD).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Espen Thiis-Evensen
Authors: Thiis-Evensen E, Sponheim J, ...
#12 Chromogranin A as a predictor of progression, regression or stable disease in ileo-cecal (midgut) carcinoid tumors
Introduction: A general characteristic for NETs is their expression of certain proteins, such as chromogranin A (CgA), which is released from the dense core vesicles of NE cells, occasionally together with cell specific hormones, such as gastrin and serotonin. Plasma CgA seems to be closely related to tumor burden of intestinal carcinoid tumors in humans.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kenneth Jensen
#158 Progression-free survival (PFS) as a primary endpoint for clinical studies in advanced neuroendocrine tumors (NETs)
Introduction: Successfully testing new antitumor agents requires primary study endpoints that are clinically important, and also provide sufficient statistical power within a timeframe and population size that is feasible for the tumor type. Using overall survival (OS) as the primary endpoint in NET studies is challenging because of the low incidence (5.25/100,000 annually), disease heterogeneity, extended survival time (Yao 2008), and confounding effects of multiple therapies. These inherent aspects of NETs make OS an extremely difficult and challenging endpoint to evaluate clinical efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Simron Singh
Authors: Singh S, Law C, ...
#313 Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors
Introduction: Antitumor effect of Somatostatin analogues has been poorly documented in metastatic typical or atypical lung carcinoid tumors (LCT).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Joël Guigay
#2128 Epigenetic Changes in DAXX and/or ATRX Negative Pancreatic Neuro-Endocrine Tumors
Introduction: The most commonly mutated genes in Pancreatic Neuroendocrine Tumors (PanNETs) are MEN1, DAXX and ATRX, which encode for proteins involved in epigenetic regulation. DAXX/ATRX mutated PanNETs are globally hypomethylated and behave clinically in a more aggressive way. Tumor pathways associated with these changes are still unclear. We hypothesize that DAXX/ATRX and MEN1 mutations mediate PanNET progression via epigenetic dysregulation.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Annunziata Di Domenico
#866 Plasma Chromogranin B as a Marker of Tumor Burden and Radiological Progression in Neuroendocrine Tumors
Introduction: Chromogranin-B (CgB) is expressed in most neuroendocrine tumors (NETs), yet little is understood about its clinical utility as a biomarker.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: David Braude